Vaccine use in primary immunodeficiency disorders

Vaccine

Volumn 32, Issue 30, 2014, Pages 3725-3731

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bacterial vaccines; Primary immunodeficiency; Primary prevention; Vaccines; Viral vaccines

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BACTERIAL VACCINE; CHICKENPOX VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 12; LIVE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

ADAPTIVE IMMUNITY; ATAXIA TELANGIECTASIA; CHEDIAK HIGASHI SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT DEFICIENCY; DIGEORGE SYNDROME; DRUG SAFETY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOSTIMULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LEUKOCYTE ADHESION DEFICIENCY; PHAGOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SERUM BACTERICIDAL ANTIBODY ASSAY; SHWACHMAN SYNDROME; SPECIFIC POLYSACCHARIDE ANTIBODY DEFICIENCY; WISKOTT ALDRICH SYNDROME; ADVERSE EFFECTS; BACTERIAL INFECTIONS; IMMUNOLOGY; VACCINATION; VIRUS DISEASES;

BACTERIAL INFECTIONS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; VACCINATION; VACCINES; VIRUS DISEASES;

EID: 84922249490     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.022     Document Type: Review

References (65)

1. Ballow M., Notarangelo L., Grimbacher B., Cunningham-Rundles C., Stein M., Helbert M., et al. Immunodeficiencies. Clin Exp Immunol 2009, 158:14-22.
2. Yong P.L., Boyle J., Ballow M., Boyle M., Berger M., Bleesing J., et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010, 135:255-263.
3. Notarangelo L.D. Primary immunodeficiencies. J Allergy Clin Immunol 2010, 125(2 Suppl. 2):S182-S194.
4. Rubin L.G., Levin M.J., Ljungman P., Davies E.G., Avery R., Tomblyn M., et al. 2013 IDSA clinical practice guideline for vaccination in the immunocompromised host. Clin Infect Dis 2014, 58:e44-e100.
5. Parvaneh N., Casanova J.L., Notarangelo L.D., Conley M.E. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol 2013, 131:314-323.
6. García J.M., Español T., Gurbindo M.D., Casas C. Update on the treatment of primary immunodeficiencies. Allergol Immunopathol (Madr) 2007, 35:184-192.
7. Abolhassani H., Sagvand B.T., Shokuhfar T., Mirminachi B., Rezaei N., Aghamohammadi A. A review on guidelines for management and treatment of common variable immunodeficiency. Expert Rev Clin Immunol 2013, 9:561-574.
8. Riminton D.S., Limaye S. Primary immunodeficiency diseases in adulthood. Intern Med J 2004, 34:348-354.
9. Papadopoulou-Alataki E., Hassan A., Davies E.G. Prevention of infection in children and adolescents with primary immunodeficiency disorders. Asian Pac J Allergy Immunol 2012, 30:249-258.
10. McCusker C., Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol 2011, 7(Suppl. 1):S11.
11. Rosenzweig S.D., Holland S.M. Phagocyte immunodeficiencies and their infections. J Allerg Clin Immunol 2004, 113:620-626.
12. Dinauer M.C. Disorders of neutrophil function: an overview. Methods Mol Biol 2014, 1124:501-515.
13. Katz P., Zaytoun A.M., Fauci A.S. Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest 1982, 69:1231-1238.
14. Notarangelo L.D., Fischer A., Geha R.S., Casanova J.L., Chapel H., Conley M.E., et al. Primary immunodeficiencies: 2009 update International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies. J Allergy Clin Immunol 2009, 124:1161-1178.
15. Kaplan J., De Domenico I., Ward D.M. Chediak-Higashi syndrome. Curr Opin Hematol 2008, 15:22-29.
16. Norouzi S., Aghamohammadi A., Mamishi S., Rosenzweig S.D., Rezaei N. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect 2012, 64:543-554.
17. Oyachi N., Obana K., Suzuki T., Kimura S., Chino K., Oyama T., Costal B.C.G. osteomyelitis developing 1 year after BCG vaccination. Pediatr Int 2013, 55:641-643.
18. Cheent K., Nolan J., Shariq S., Kiho L., Pal A., Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010, 4:603-605.
19. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000, 79:155-169.
20. Ram S., Lewis L.A., Rice P.A. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010, 23:740-780.
21. Attwood J.T., Williams Y., Feighery C. Impaired IgG responses in a child with homozygous C2 deficiency and recurrent pneumococcal septicaemia. Acta Paediatr 2001, 90:99-101.
22. Berkel A.I. Studies of immune response in a patient with selective complete C1q deficiency. Turk J Pediatr 1993, 35:221-226.
23. Keiser P.B., Broderick M. Meningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody response. Hum Vaccin Immunother 2012, 8:582-586.
24. Andreoni J., Kayhty H., Densen P. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis 1993, 168:227-231.
25. Biselli R., Casapollo I., D'Amelio R., Salvato S., Matricardi P.M., Brai M. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol 1993, 37:644-650.
26. Platonov A.E., Beloborodov V.B., Pavlova L.I., Vershinina I.V., Kayhty H. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1995, 100:32-39.
27. Platonov A.E., Vershinina I.V., Kuijper E.J., Borrow R., Kayhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003, 21:4437-4447.
28. Schlesinger M1, Kayhty H., Levy R., Bibi C., Meydan N., Levy J. Phagocytic killing and antibody response during the first year after tetravalent meningococcal vaccine in complement-deficient and in normal individuals. Clin Immunol 2000, 20:46-53.
29. Fijen C.A., Kuijper E.J., Drogari-Apiranthitou M., Van Leeuwen Y., Daha M.R., Dankert J. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998, 114:362-369.
30. Drogari-Apiranthitou M., Fijen C.A., Van De Beek D., Hensen E.F., Dankert J., Kuijper E.J. Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients. Clin Exp Immunol 2000, 119:311-316.
31. Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Meissner H.C., et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013, 62(RR-2):1-28.
32. Centers for Disease Control and Prevention (CDC) Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010, 59:687-688.
33. Publication W.H.O. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012, 30:4717-4718.
34. Mansouri D., Adimi P., Mirsaeidi M., Mansouri N., Khalilzadeh S., Masjedi M.R., et al. Inherited disorders of the IL-12-IFN-gamma axis in patients with disseminated BCG infection. Eur J Pediatr 2005, 164:753-757.
35. Zhang S.Y., Boisson-Dupuis S., Chapgier A., Yang K., Bustamante J. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008, 226:29-40.
36. Dupuis S., Jouanguy E., Al-Hajjar S., Fieschi C., Al-Mohsen I.Z., Al-Jumaah S., et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 2003, 33:388-391.
37. Ozkan H., Atlihan F., Genel F., Targan S., Gunvar T. IgA and/or IgG subclass deficiency in children with recurrent respiratory infections and its relationship with chronic pulmonary damage. J Investig Allergol Clin Immunol 2005, 15:69-74.
38. Ruuskanen O., Nurkka A., Helminen M., Viljanen M.K., Käyhty H., Kainulainen L. Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up. Clin Exp Immunol 2013, 172:238-244.
39. Aghamohammadi A., Mohammadi J., Parvaneh N., Rezaei N., Moin M., Espanol T., et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol 2008, 147:87-92.
40. Savilahti E., Klemola T., Carlsson B., Mellander L., Stenvik M., Hovi T. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. J Clin Immunol 1988, 8:89-94.
41. Finocchi A., Di Cesare S., Romiti M.L., Capponi C., Rossi P., Carsetti R., et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). Pediatr Allergy Immunol 2006, 17:382-388.
42. Sanders L.A., Rijkers G.T., Kuis W., Tenbergen-Meekes A.J., de Graeff-Meeder B.R., Hiemstra I., et al. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993, 91(1 Pt 1):110-119.
43. Tuerlinckx D., Vermeulen F., Pékus V., de Bilderling G., Glupczynski Y., Collet S., et al. Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies. Clin Exp Immunol 2007, 149:295-302.
44. Cheng Y.K., Decker P.A., O'Byrne M.M., Weiler C.R. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol 2006, 97:306-311.
45. Lakshman R., Gennery A.R., Arkwright P.D., Flood T., Abinun M., Spickett G., et al. Assessing immune responses to pneumococcal vaccines. Arch Dis Child 2003, 88:648-649.
46. Shrimpton A., Duddridge M., Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006, 24:3574-3580.
47. Schubert R., Reichenbach J., Rose M., Zielen S. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004, 23:269-270.
48. Ballow O.M. Vaccines in the assessment of patients for immune deficiency. J Allergy Clin Immunol 2012, 130:283-284.
49. Perez E.E., Bokszczanin A., McDonald-McGinn D., Zackai E.H., Sullivan K.E. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003, 112:e325.
50. Al-Sukaiti N., Reid B., Lavi S., Al-Zaharani D., Atkinson A., Roifman C.M., et al. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol 2010, 126:868-869.
51. Hofstetter A.M., Jakob K., Klein N.P., Dekker C.L., Edwards K.M., Halsey N.A., et al. Live vaccine use and safety in DiGeorge syndrome. Pediatrics 2014, 133:e946-e954.
52. de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara B.A. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine 2012, 30:7561-7565.
53. Stephan J.L., Vlekova V., Le Deist F., Blanche S., Donadieu J., De Saint-Basile G., et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993, 123:564-572.
54. Yeganeh M., Heidarzade M., Pourpak Z., Parvaneh N., Rezaei N., Gharagozlou M., et al. Severe combined immunodeficiency: a cohort of 40 patients. Pediatr Allergy Immunol 2008, 19:303-306.
55. Izhar M., DeSilva L., Joysey H.S., Hormaeche C.E. Moderate immunodeficiency does not increase susceptibility to Salmonella typhimurium aroA live vaccines in mice. Infect Immun 1990, 58:2258-2261.
56. Shaghaghi M., Parvaneh N., Ostad-Rahimi P., Fathi S.M., Shahmahmoodi S., Abolhassani H., et al. Combined immunodeficiency presenting with vaccine-associated paralytic poliomyelitis: a case report and narrative review of literature. Immunol Invest 2013, (Epub Dec 2).
57. Canessa C., Romano F., Lippi F., Bianchi L., Kashef S., Rezaei N., et al. Bcgitis and vaccine-derived poliovirus infection in a patient with a novel deletion in RAG1 binding site. Int J Immunopathol Pharmacol 2013, 26:511-515.
58. Centers for Disease Control and Prevention (CDC) Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR Morb Mortal Wkly Rep 2010, 59:687-688.
59. Bakare N., Menschik D., Tiernan R., Hua W., Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010, 28:6609-6612.
60. Rezaei N., Aghamohammadi A., Siadat S.D., Moin M., Pourpak Z., Nejati M., et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol 2008, 15:607-611.
61. Ko J., Radigan L., Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 2005, 116:37-41.
62. Goldacker S., Draeger R., Warnatz K., Huzly D., Salzer U., Thiel J., et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007, 124:294-303.
63. van Assen S., Holvast A., Telgt D.S.C., Benne C.A., de Haan A., Westra J., et al. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin Immunol 2010, 136:228-235.
64. van Assen S., de Haan A., Holvast A., Horst G., Gorter L., Westra J., et al. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. Clin Immunol 2011, 141:161-168.
65. Jawad A.F., Prak E.L., Boyer J., McDonald-McGinn D.M., Zackai E., McDonald K., et al. A prospective study of influenza vaccination and a comparison of immunologic parameters in children and adults with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Clin Immunol 2011, 31:927-935.